IPSEY
Price:
$28.55
Market Cap:
$8.46B
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and a...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2012-08-03
Stock Exchange
PNK
Ticker
IPSEY
According to Ipsen S.A.’s latest financial reports and current stock price. The company's current PE Ratio is 23.99. This represents a change of 105.05% compared to the average of 11.70 of the last 4 quarters.
The mean historical PE Ratio of Ipsen S.A. over the last ten years is 6.11. The current 23.99 PE Ratio has changed 39.14% with respect to the historical average. Over the past ten years (40 quarters), IPSEY's PE Ratio was at its highest in in the December 2024 quarter at 20.21. The PE Ratio was at its lowest in in the December 2011 quarter at -18.73.
Average
6.11
Median
19.00
Minimum
-119.57
Maximum
30.92
Discovering the peaks and valleys of Ipsen S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 91.23%
Maximum Annual PE Ratio = 30.92
Minimum Annual Increase = -595.24%
Minimum Annual PE Ratio = -119.57
Year | PE Ratio | Change |
---|---|---|
2024 | 26.49 | 91.23% |
2023 | 13.85 | 7.60% |
2022 | 12.87 | 24.03% |
2021 | 10.38 | 0.43% |
2020 | 10.33 | -108.64% |
2019 | -119.57 | -595.24% |
2018 | 24.14 | -21.92% |
2017 | 30.92 | 22.93% |
2016 | 25.15 | -5.32% |
2015 | 26.57 | 15.16% |
The current PE Ratio of Ipsen S.A. (IPSEY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
17.74
5-year avg
14.79
10-year avg
6.11
Ipsen S.A.’s PE Ratio is greater than Esperion Therapeutics, Inc. (-1.03), less than Takeda Pharmaceutical Company Limited (31.23), greater than Athenex, Inc. (-0.01), greater than Aquestive Therapeutics, Inc. (-4.19), greater than Collegium Pharmaceutical, Inc. (21.90), greater than Dr. Reddy's Laboratories Limited (3.58), less than Kamada Ltd. (26.11), greater than Pacira BioSciences, Inc. (-11.54), greater than Perrigo Company plc (-20.97), greater than Emergent BioSolutions Inc. (-2.74), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Intra-Cellular Therapies, Inc. (-182.12), greater than DURECT Corporation (-3.98), greater than Lifecore Biomedical, Inc. (-5.72), greater than Rockwell Medical, Inc. (-130.49), greater than Agile Therapeutics, Inc. (-0.65), greater than Alimera Sciences, Inc. (-20.50), greater than Shuttle Pharmaceuticals Holdings, Inc. (-0.21), greater than Mallinckrodt plc (0.00), greater than Journey Medical Corporation (-18.89),
Company | PE Ratio | Market cap |
---|---|---|
-1.03 | $158.92M | |
31.23 | $44.41B | |
-0.01 | $2.33M | |
-4.19 | $236.40M | |
21.90 | $971.66M | |
3.58 | $12.03B | |
26.11 | $399.08M | |
-11.54 | $1.20B | |
-20.97 | $3.72B | |
-2.74 | $360.40M | |
-11.74 | $2.21B | |
-182.12 | $14.05B | |
-3.98 | $19.56M | |
-5.72 | $255.29M | |
-130.49 | $34.52M | |
-0.65 | $10.43M | |
-20.50 | $301.29M | |
-0.21 | $2.37M | |
0.00 | $4.52M | |
-18.89 | $160.34M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ipsen S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ipsen S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ipsen S.A.'s PE Ratio?
How is the PE Ratio calculated for Ipsen S.A. (IPSEY)?
What is the highest PE Ratio for Ipsen S.A. (IPSEY)?
What is the 3-year average PE Ratio for Ipsen S.A. (IPSEY)?
What is the 5-year average PE Ratio for Ipsen S.A. (IPSEY)?
How does the current PE Ratio for Ipsen S.A. (IPSEY) compare to its historical average?